Based on the Biocon Limited stock forecast from 4 analysts, the average analyst target price for Biocon Limited is INR 269.40 over the next 12 months. Biocon Limited’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Biocon Limited is Bullish , which is based on 8 positive signals and 3 negative signals. At the last closing, Biocon Limited’s stock price was INR 271.15. Biocon Limited’s stock price has changed by +2.22% over the past week, +7.51% over the past month and +18.48% over the last year.
No recent analyst target price found for Biocon Limited
No recent average analyst rating found for Biocon Limited
Company Overview Biocon Limited
Biocon Limited, a biopharmaceutical company, manufactures pharmaceuticals, and medicinal chemical and botanical products. The company operates through Generics, Novel Biologics, Biosimilars, and Research Services segments. It focuses in the areas of diabetes, oncology, immunology, ophthalmology, and bone health diseases. In addition, the company is involved in the integrated discovery, development, and manufacturing services for small and large molecules. It serves customers in approximately 120 countries. The company was incorporated in 1978 and is headquartered in Bengaluru, India. Address: 20th KM, Hosur Road, Bengaluru, India, 560100 Read Less
Biocon Limited, a biopharmaceutical company, manufactures pharmaceuticals, and medicinal chemical and botanical products. The company operates through Generics, Novel Biologics, Biosimilars, and Research Services segments. It focuses in the areas of diabetes, oncology, immunology...Read More
Frequently Asked Questions About Biocon Limited (BIOCON:NSE) Stock
Based on ratings from 4 analysts Biocon Limited's stock is Buy . Stock Target Advisor's fundamental analysis is Bullish . The stock has 2 buy, sell and 3 hold ratings.
BIOCON:NSE stock's dividend yield is 0.57%.
Our analysis grades BIOCON:NSE stock's dividend yield at A+. This means that BIOCON:NSE stock's dividend yield is above 100% of the stocks in the Biotechnology sector in the NSE exchange.
Based on this BIOCON:NSE may be a good dividend stock for its sector.
Based on targets from 4 analysts, the average taret price for BIOCON:NSE is INR 269.40 over the next 12 months. The maximum analyst target price is INR 332 while the minimum anlayst target price is INR 220.
BIOCON:NSE stock's Price/Earning ratio is 27.06.
Our analysis grades BIOCON:NSE stock's Price / Earning ratio at C-. This means that BIOCON:NSE stock's Price/Earning ratio is above 30% of the stocks in the Biotechnology sector in the NSE exchange.
Based on this BIOCON:NSE may be undervalued for its sector.
The last closing price of BIOCON:NSE's stock was INR 271.15.
The most recent market capitalization for BIOCON:NSE is INR 324.57B.
Based on targets from 4 analysts, the average taret price for BIOCON:NSE is projected at INR 269.40 over the next 12 months.
This means that BIOCON:NSE's stock price may go down by -0.65% over the next 12 months.
We can't find any ETFs which contains Biocon Limited's stock.
As per our most recent records Biocon Limited has 16,545 Employees.
Biocon Limited's registered address is 20th KM, Hosur Road, Bengaluru, India, 560100.
You can get more information about it from Biocon Limited's website at https://www.biocon.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Underpriced on free cash flow basis
The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
Superior Dividend Growth
This stock has shown top quartile dividend growth in the previous 5 years compared to its sector
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for BIOCON:NSE !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
Stocktwits
